Vaughn B. Himes Sells 1,795 Shares of Seagen Inc. (NASDAQ:SGEN) Stock

Seagen Inc. (NASDAQ:SGENGet Free Report) insider Vaughn B. Himes sold 1,795 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $206.97, for a total transaction of $371,511.15. Following the transaction, the insider now owns 51,439 shares in the company, valued at approximately $10,646,329.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seagen Price Performance

Shares of SGEN opened at $207.91 on Friday. Seagen Inc. has a 1-year low of $116.08 and a 1-year high of $210.50. The stock has a market cap of $39.02 billion, a PE ratio of -53.45 and a beta of 0.50. The firm has a 50-day simple moving average of $195.59 and a two-hundred day simple moving average of $193.82.

Seagen (NASDAQ:SGENGet Free Report) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.35). The business had revenue of $603.83 million during the quarter, compared to analyst estimates of $555.68 million. Seagen had a negative net margin of 33.54% and a negative return on equity of 26.46%. As a group, sell-side analysts expect that Seagen Inc. will post -3.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SGEN. StockNews.com assumed coverage on shares of Seagen in a research report on Thursday. They set a “hold” rating on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $229.00 price target on shares of Seagen in a research report on Thursday, August 3rd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $190.47.

View Our Latest Stock Report on SGEN

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. KB Financial Partners LLC purchased a new position in Seagen in the first quarter worth approximately $25,000. Private Trust Co. NA lifted its position in shares of Seagen by 87.1% during the 2nd quarter. Private Trust Co. NA now owns 131 shares of the biotechnology company’s stock worth $25,000 after buying an additional 61 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Seagen by 61.6% during the 1st quarter. Parallel Advisors LLC now owns 181 shares of the biotechnology company’s stock worth $37,000 after buying an additional 69 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Seagen during the 2nd quarter worth approximately $375,000. Finally, Lindbrook Capital LLC lifted its position in shares of Seagen by 79.8% during the 1st quarter. Lindbrook Capital LLC now owns 196 shares of the biotechnology company’s stock worth $40,000 after buying an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 84.26% of the company’s stock.

Seagen Company Profile

(Get Free Report)

Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Featured Articles

Insider Buying and Selling by Quarter for Seagen (NASDAQ:SGEN)

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.